2.65
+0.29(+12.29%)
Currency In USD
| Previous Close | 2.36 |
| Open | 2.35 |
| Day High | 2.66 |
| Day Low | 2.34 |
| 52-Week High | 3.3 |
| 52-Week Low | 1.01 |
| Volume | 1.89M |
| Average Volume | 1.52M |
| Market Cap | 751.73M |
| PE | -6.79 |
| EPS | -0.39 |
| Moving Average 50 Days | 2.11 |
| Moving Average 200 Days | 1.62 |
| Change | 0.29 |
If you invested $1000 in Erasca, Inc. (ERAS) since IPO date, it would be worth $152.04 as of November 13, 2025 at a share price of $2.65. Whereas If you bought $1000 worth of Erasca, Inc. (ERAS) shares 3 years ago, it would be worth $312.87 as of November 13, 2025 at a share price of $2.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015
GlobeNewswire Inc.
Nov 06, 2025 1:00 PM GMT
The issued patent provides intellectual property protection for ERAS-0015 and related compositions until at least 2043 Initial Phase 1 monotherapy data for ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 SAN DIEGO, Nov. 06, 2025 (GLOBE
Erasca to Present at Upcoming Conferences in November
GlobeNewswire Inc.
Nov 04, 2025 1:00 PM GMT
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to
Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, t